National Bank of Canada
IMCR icon

National Bank of Canada’s Immunocore IMCR Stock Holding History

National Bank of Canada’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-37,400
Closed -$2.2M – 2760
2024
Q1 		$2.2M Buy
+37,400
New +$2.57M ﹤0.01% 991

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

National Bank of Canada's IMCR Position: Q2 2024 in Review

National Bank of Canada sold out of Immunocore (IMCR) in Q2 2024, closing a stake of 37,400 shares — an estimated $2.2M sold.

National Bank of Canada first reported a position in IMCR in Q1 2024 and held it in 1 quarter. The position peaked at $2.2M in Q1 2024. 138 funds tracked by Wall St. Rank hold IMCR as of Q2 2024.

  • National Bank of Canada reported no remaining Immunocore position as of Q2 2024 after selling out during the quarter.
  • National Bank of Canada sold 37,400 Immunocore shares in Q2 2024, an estimated $2.2M.
  • National Bank of Canada first reported a position in Immunocore in Q1 2024 and held it in 1 quarter.
  • National Bank of Canada's Immunocore position peaked at $2.2M in Q1 2024.
  • 138 funds tracked by Wall St. Rank held Immunocore as of Q2 2024.

Based on National Bank of Canada's 13F filing for Q2 2024, filed 2 Aug 2024.